Characterizing complex and competing drug–drug interactions between the antiviral regimen of glecaprevir and pibrentasvir with rifampin or carbamazepine
Open Access
- 23 January 2023
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (4) , 593-605
Abstract
The fixed‐dose combination of the direct acting antivirals glecaprevir (GLE) and pibrentasvir (PIB) is an oral, once‐daily treatment for all six major genotypes of chronic hepatitis C virus infection. A single and multiple‐dose rifampin study (N = 12) and a carbamazepine study (N = 12) were conducted in healthy subjects to evaluate the effects of CYP3A/P‐gp induction and OATP inhibition on the pharmacokinetics of GLE and PIB. In study 1, GLE 300 mg + PIB 120 mg was administered as a single dose either alone, after single and multiple daily doses of rifampin 600 mg, or 24 h after the last rifampin dose. In study 2, GLE 300 mg + PIB 120 mg was administered as a single dose either alone or after multiple doses of carbamazepine 200 mg. Relative to GLE + PIB alone, exposure of GLE was significantly increased by the first co‐administered rifampin dose due to OATP inhibition, significantly decreased 24 h after the last rifampin dose due to CYP3A/P‐gp induction, and slightly increased when co‐administered with steady‐state rifampin due to a combination of inhibition and induction forces. Exposure of PIB was not affected when co‐administered with the first rifampin dose but was significantly decreased with steady‐state rifampin co‐administration, or 24 h after the last rifampin dose due to P‐gp induction. Carbamazepine significantly decreased GLE and PIB exposure, mainly attributed to P‐gp induction. The regimens tested were generally well‐tolerated by the subjects and no new safety issues were identified.Keywords
This publication has 42 references indexed in Scilit:
- Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug developmentBritish Journal of Pharmacology, 2010
- Elucidating Rifampin's Inducing and Inhibiting Effects on Glyburide Pharmacokinetics and Blood Glucose in Healthy Volunteers: Unmasking the Differential Effects of Enzyme Induction and Transporter Inhibition for a Drug and Its Primary MetaboliteClinical Pharmacology & Therapeutics, 2008
- Effect of pregnane X receptor ligands on transport mediated by human OATP1B1 and OATP1B3European Journal of Pharmacology, 2008
- Association between HLA‐B*1502 Allele and Antiepileptic Drug‐Induced Cutaneous Reactions in Han ChineseEpilepsia, 2007
- Relative Activation of Human Pregnane X Receptor versus Constitutive Androstane Receptor Defines Distinct Classes of CYP2B6 and CYP3A4 InducersThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Polypharmacy and Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2005
- A marker for Stevens–Johnson syndromeNature, 2004
- Pharmacokinetic Interactions with RifampicinClinical Pharmacokinetics, 2003
- Rifamycin SV and rifampicin exhibit differential inhibition of the hepatic rat organic anion transporting polypeptides, Oatp1 and Oatp2Hepatology, 2000
- Clinically Significant Pharmacokinetic Drug Interactions with CarbamazepineClinical Pharmacokinetics, 1996